Introduction
Accumulating evidence suggests that a series of genetic alterations such as activation of oncogenes and inactivation of tumor suppressor genes is involved in the pathogenesis of lung cancer (Minna et al., 1997) . According to Knudson's two-hit theory, tumor suppressor genes are inactivated by recessive mutation in one allele and loss of the other allele containing the wild-type function (Knudson, 1971) . Frequent LOH is consequently considered to be a hallmark of chromosomal regions harboring tumor suppressor genes. Cytogenetic and molecular analyses of lung cancers have revealed frequent occurrence of multiple chromosomal deletions involving 3p, 5q, 8p, 9p, 11p, 13q, 17p, 18q and 22q (Minna et al., 1997) .
It has been shown that 17p is one of the most frequently aected chromosomal regions in lung cancer (Yokota et al., 1987) . We previously reported that, in close association with a past history of smoking, p53 at 17p13.1 is altered in all histologic types of lung cancers at frequencies of *75% in small cell lung cancer (SCLC) and *50% in non-small cell lung cancer (NSCLC) and that wild-type p53 could function as a potent in vitro and in vivo growth suppressor in human lung cancers (Suzuki et al., 1992; Takahashi et al., 1989 Takahashi et al., , 1991 Takahashi et al., , 1992 . These results indicated that the p53 gene at 17p13.1 is indeed a molecular target for the frequent 17p deletions in lung cancer.
17p deletions and p53 mutations have been shown to be also common in various types of other human neoplasms (Greenblatt et al., 1994; Vogelstein et al., 1988) . It should be noted, however, that detailed analyses of 17p deletions have suggested the existence of an additional tumor suppressor gene(s) at 17p13.3 that is independent of and distal to the p53 gene at 17p13.1 in certain types of malignancies including breast cancer (Coles et al., 1990; Cornelis et al., 1994; Merlo et al., 1994; Radford et al., 1995; Sato et al., 1990; Stack et al., 1995) , ovarian cancer (Phillips et al., 1996; Schultz et al., 1996) , primitive neuroectodermal tumor (Biegel et al., 1992; Haataja et al., 1997) , medulloblastoma (Cogen et al., 1992) , astrocytoma (Saxena et al., 1992) , hepatocellular carcinoma (Fujimori et al., 1991) , bladder cancer (Williamson et al., 1994) and uterine cervical cancer (Park et al., 1995) . In contrast, detailed deletion mapping of 17p has not been reported in lung cancers to date and thus very little information is available with regard to the possibility of the existence of an additional tumor suppressor gene(s).
In the present study, we examined 100 primary lung cancer cases for a detailed analysis of the minimum deleted region(s) on 17p in reference to the p53 gene status. We here report on the possible existence of an additional tumor suppressor gene at 17p13.3, which might play a role in lung carcinogenesis in an earlier phase than the p53 gene.
Results

LOH at 17p13.3 is a frequent event in human lung cancers
One hundred cases of primary lung cancers representing all four major histologic subtypes were examined by using nine DNA polymorphic markers on chromosome 17, including seven markers at 17p13. LOH at one or more loci at 17p13 was observed in 13 (93%) of 14 SCLCs, 29 (54%) of 54 adenocarcinomas, 21 (75%) of 28 squamous cell carcinomas and two (50%) of four large cell carcinomas (Figures 1 and 2 ; Table 1 ). Prevalence of LOH at 17p13.3 was found to be even greater than that at the p53 locus, while D17S5 exhibited the highest frequency of LOH among the 17p13 markers examined. Adenocarcinomas showed LOH at 17p13.3 with an incidence of over 40%, while LOH at the p53 locus was observed in 34% of the informative cases. Squamous cell carcinomas exhibited an extremely high incidence (72%) of LOH at D17S5, even higher than that at the p53 locus (61%), whereas LOH was considerably less frequent at the DNA markers mapped between p53 and D17S5 (44% at D17S513 and 47% at D17S379).
LOH at 17p13.3 precedes to that at 17p13.1 and p53 mutations Of the 100 cases examined, 88 were informative at both the p53 locus and DNA markers at 17p13.3 and thus useful for studying the relationship between LOH at these two chromosomal regions ( We also examined the relationship between LOH at 17p13.3 and p53 mutations ( Table 2 ). Among the 99 cases informative for at least one or more loci at 17p13.3, LOH at 17p13.3 was observed in 63 (64%) and p53 mutations were observed in 44 (44%). Thirtynine (89%) of the 44 cases carrying p53 mutations had LOH at 17p13.3, while 44% (24 of 55) of the cases Figure 1 Results of analysis for LOH on the short arm of chromosome 17 in 100 primary lung cancer cases representing all four major histologic subtypes. The p53 gene status of each case is shown at the right side of the ®gure. Physical location for the markers is shown below the karyogram. LOH, loss of heterozygosity; N.I., not informative; blank, not examined. SCLC, small cell lung cancer; NSCLC, non-small cell lung cancer; AD, adenocarcinoma; SQ, squamous cell carcinoma; LA, large cell carcinoma Figure 2 LOH at 17p13.3 in four representative lung cancer specimens. Case 25 shows LOH at D17S1866 and D17S5 while case 27 exhibits a small interstitial deletion surrounding D17S695. Case 62 shows LOH at D17S1866, D17S695, D17S379, D17S513 and TP53. In contrast, loss of the entire short arm of chromosome 17 is suggested in an SCLC specimen of case 7. Open and solid arrowheads refer to larger and smaller alleles, respectively. N, normal; T, tumor without p53 mutations also did so. These results indicated that LOH at 17p13.3 could be detected even in lung cancers without apparent p53 mutations and/or LOH at 17p13.1.
A commonly deleted region(s) independent of the p53 locus at 17p13.1 appear to exist at 17p13.3
Detailed deletion mapping in the present study identi®ed 27 cases which carried 17p13.3 deletions but retained heterozygosity at the p53 locus and/or at least one or more markers mapped between p53 and the deleted 17p13.3 markers (Figure 3) . Consequently, the chromosomal region between D17S379 and D17S695, which included the most frequently deleted marker D17S5, was found to be aected in the majority of the cases. It is noteworthy, however, that three cases (cases 22, 23 and 64) exhibited small deletions centromeric to the D17S5 locus, suggesting that the putative tumor suppressor gene might reside between D17S379 and D17S5. In addition, several specimens such as cases 29, 59, 60, 62 and 91 exhibited LOH which was con®ned to a telomeric region, showing an overlap of deletions telomeric to the D17S695 locus. These results suggest the possible existence of two separate tumor suppressor loci at 17p13.3.
Discussion
It is well accepted that 17p is one of the chromosomal regions most frequently aected by LOH in human lung cancers (Yokota et al., 1987) , while previous studies including those by ourselves have indicated that the p53 gene at 17p13.1 is undoubtedly a genuine target for frequent genetic alterations in the multistep carcinogenesis of this fatal disease (Chiba et al., 1990; Suzuki et al., 1992; Takahashi et al., 1989 Takahashi et al., , 1991 Takahashi et al., , 1992 . The present study has demonstrated a separate, commonly deleted region(s) at 17p13.3 in addition to (9) 2/4 (50) 0/4 (0) a Numbers in parentheses represent the percentage of informative tumors that were scored as having LOH Figure 3 Extent of LOH at 17p13.3 in lung cancers showing small deletions excluding the p53 locus. The extent is indicated with shaded boxes. Closed circle, LOH; open circle, retention of both alleles; 7, not informative; blank, not examined. AD, adenocarcinoma; SQ squamous cell carcinoma the p53 locus at 17p13.1. Furthermore, we have shown that LOH at 17p13.3 is even more frequent than that at 17p13.1 and that this often occurs in the absence of p53 mutations and 17p13.1 deletions. These results suggest that in addition to the p53 gene at 17p13.1, an as yet unidenti®ed tumor suppressor gene(s) at 17p13.3 may be involved in the pathogenesis of lung cancers and might play a role in lung carcinogenesis possibly in an earlier phase than the p53 gene.
Evidence has been established previously in lung cancers for the possible existence of multiple tumor suppressor genes within the same chromosomal arm. We have reported that there might be three independent tumor suppressor genes on the short arm of chromosome 3, i.e., 3p14.2, 3p21.3, and 3p25 (Hibi et al., 1992) . While others have reported similar ®ndings for 3p deletions (Whang-Peng et al., 1991; Yokoyama et al., 1992) , Todd et al. (1997) recently suggested the possibility of the presence of two independent tumor suppressor genes even within the same chromosomal band, i.e. 3p21.3. The chromosomal regions 11p13 and 11p15 are also suspected of containing putative tumor suppressor genes for lung cancers (Bepler and Garcia-Blanco, 1994; Ludwig et al., 1991; Weston et al., 1989) , while a recent study of ours suggested that the p57 KIP2 cyclin-dependent kinase inhibitor gene might be a target for the 11p15 deletions in lung cancers (Kondo et al., 1996) .
In the present study, we noted that all cases of SCLC, a tumor type carrying very frequent p53 mutations, had lost heterozygosity at all informative loci on 17p, except for just one case, and that NSCLC specimens carrying p53 mutations also tended to show large chromosomal deletions. In this regard, Chung et al. (1995) reported that bronchial epithelial dysplasia specimens, which showed small interstitial deletions on 3p, proceeded to lose the whole short arm of chromosome 3 in the invasive tumors removed later from the same patients. This suggests progressive involvement of multiple tumor suppressor genes on the same chromosomal arm (Chung et al., 1995) . It will be of interest to examine whether similar progressive loss is also detectable on the short arm of chromosome 17 during the process of tumor formation and its progression.
The telomeric border of the commonly deleted region identi®ed in the present study was de®ned by D17S695, while the centromeric border was found to be D17S379. This chromosomal region included D17S5, a DNA marker found to be most frequently aected. Since there were three cases (cases 22, 23 and 64) with small deletions in which D17S5 was not involved, the putative location of the target gene could be further narrowed down to between D17S379 and D17S5, which have been shown by Ledbetter et al. (1990) to be separated by about 320 kb. In addition, it should also be noted that several specimens exhibited LOH of a more telomeric region. These results suggest the possibility that there might be two independent tumor suppressor loci at 17p13.3.
Previous studies have also identi®ed commonly deleted regions at 17p13.3 in other types of human cancers. Minimum overlaps of deletions in breast cancer were reported to be bordered by the loci D17S34 and D17S5 (Cornelis et al., 1994) , D17S34 and D17S28 (Merlo et al., 1994) or D17S849 and D17S379 (Radford et al., 1995) , which overlap the commonly deleted region in lung cancers. Recent studies on breast cancer have further narrowed the overlap down to an interval between D17S849 and D17S926, which contains D17S695 used in the present study (Stack et al., 1995) . Phillips et al. (1996) and Schultz et al. (1996) claimed that a region of about 15 kb in length adjacent to the D17S5 locus appeared to represent a minimum overlap of deletions in ovarian cancers. Neural tumors including primitive neuroectodermal tumors, medulloblastomas, and astrocytomas have been shown to carry frequent deletions around the D17S34 locus (Biegel et al., 1992; Cogen et al., 1992; Saxena et al., 1992) . Since D17S695 has been demonstrated to be genetically closely linked to D17S34 (Gerken et al., 1995) and proximal to D17S34 (Stack et al., 1995) , an additional distal region commonly deleted in lung cancers (e.g. cases 29, 59, 60, 62 and 91) appears to overlap with the region frequently deleted in neural tumors. These data suggest the possibility that the putative lung cancer suppressor gene(s) at 17p13.3 might also be involved in the pathogenesis of cancers of diverse origins including breast cancer, ovarian cancer and neural tumors.
To date, several genes have been suggested as candidate tumor suppressor genes within the chromosomal region 17p13.3. HIC-1, which was isolated from its close proximity to the D17S5 locus, was shown to possess growth inhibitory activity (Wales et al., 1995) . Although the presence of frequent somatic mutations, a manifestation of authenticity as a target gene, has hitherto not been detected in the HIC-1 gene in lung cancers, expression of HIC-1 was shown to be repressed due to tumor-speci®c hypermethylation in lung cancers as well as in other types of human cancers (Wales et al., 1995) . It is, however, also possible that there might be another target gene inactivated by hypermethylation, since the hypermethylated lesion surrounding D17S5 at 17p13.3 was previously estimated by the same group to be over 300 ± 500 kb in lung cancers as well as in colon cancers (Makos et al., 1992) . Another good candidate at 17p13.3 is the ROX/Mnt gene, which was recently isolated as a novel MAX-interacting protein with the suggested function of a myc antagonist (Hurlin et al., 1997; Meroni et al., 1997) . D17S379, a centromeric border of the commonly deleted region identi®ed here, has been shown to be within the ROX/Mnt gene (Meroni et al., 1997) . In addition, Schultz et al. (1996) recently cloned OVCA1 and OVCA2 from a genomic region adjacent to D17S5 and showed that their expressions were repressed in the majority of ovarian cancers. It will be of interest to determine whether the above mentioned candidate genes are altered in lung cancers carrying 17p13.3 deletions. Should this not be the case, further positional cloning eorts will be necessary to isolate and characterize the putative tumor suppressor gene(s) at 17p13.3 in order to gain a better understanding of the molecular pathogenesis of lung cancer and possibly of other human cancers such as breast and ovarian cancers.
Materials and methods
Tumor samples
Tumor samples together with uninvolved lung tissues were collected from patients diagnosed histologically as having primary lung cancers (14 cases of SCLC, 54 cases of 17p13.3 deletions in lung cancers H Konishi et al adenocarcinoma, 28 cases of squamous cell carcinoma and four cases of large cell carcinoma). Eleven SCLC and one NSCLC tumor samples were obtained during necropsy, while three SCLC and 85 NSCLC tumor samples were collected during surgery at the Aichi Cancer Center and three other hospitals in Nagoya, Japan. All tissues were quickly frozen in liquid nitrogen and stored at 7808C until analysis. DNAs were prepared as described previously (Takahashi et al., 1989) .
DNA markers
Polymerase chain reaction (PCR) ampli®cation was performed to examine LOH at each of the STS markers. The primer pair sequences were obtained via on-line servers or previous reports and these included D17S1866 (http://www.genethon.fr) (Dib et al., 1996) , D17S695 (Gerken et al., 1995) , D17S5 (Horn et al., 1989), D17S379 (Carrozzo and Ledbetter, 1993) , D17S513 (Oliphant et al., 1991) , TP53-Alu (Futreal et al., 1991) , TP53-(CA) n (Jones and Nakamura, 1992), D17S520 (http:// gdbwww.gdb.org) and D17S250 (Weber et al., 1990) . The ordering of the markers on 17p was telomere-D17S1866-D17S695 -D17S5 -D17S379 -D17S513 -(TP53 -Alu, TP-53-(CA) n )-D17S520-centromere, according to the GeÂ neÂ thon human linkage map (Dib et al., 1996) (D17S1866), the integrated physical map of 17p13.3 generated with multicolor¯uorescent in situ hybridization by Stack et al. (1995) (D17S695 and D17S5), the pulsed-®eld gel analysis of 17p13.3 by Ledbetter et al. (1990) (D17S5 and D17S379), the genetic linkage map for human chromosome 17 by Radford et al. (1995) (D17S379, D17S513 and TP53-(CA) n and the somatic cell hybrid panel analysis by Weber (D17S520). The exact ordering of TP53-(CA) n and TP53-Alu is not available currently. The marker TP53-Alu was examined only when TP53-(CA) n marker was not informative. PCR conditions for the DNA markers were as follows: D17S1866, 30 cycles (948C for 30 s, 558C for 30 s, 728C for 1 min) after the initial denaturation at 958C for 4 min; D17S695, 30 cycles (948C for 45 s, 608C for 30 s, 728C for 1 min) in the presence of 5% dimethylsulfoxide (DMSO) after the initial denaturation at 948C for 5 min; D17S5, 30 cycles (958C for 45 s, 558C for 30 s, 728C for 2 min) after the initial denaturation at 958C for 4 min; D17S379, 30 cycles (958C for 45 s, 578C for 30 s, 728C for 1 min) in the presence of 5% DMSO after the initial denaturation at 958C for 4 min; D17S513, 30 cycles (948C for 1 min, 558C for 30 s, 728C for 1 min) in the presence of 12.5% DMSO after the initial denaturation at 948C for 5 min; TP53-Alu, 30 cycles (948C for 45 s, 558C for 30 s, 728C for 1 min) after the initial denaturation at 948C for 5 min; TP53-(CA) n , 35 cycles (948C for 45 s, 608C for 1 min) in the presence of 12.5% DMSO after the initial denaturation at 948C for 3 min; D17S520, 30 cycles (948C for 45 s, 528C for 30 s, 728C for 1 min) after the initial denaturation at 948C for 5 min; and D17S250, 30 cycles (948C for 45 s, 558C for 30 s, 728C for 1 min) after the initial denaturation at 948C for 5 min. The entire PCR ampli®cation was carried out using either Taq polymerase (Takara, Ohtsu, Japan) or Ex Taq polymerase (only for D17S520) (Takara) in the presence of [ 32 P]dCTP, followed by a ®nal extension step at 728C for 10 min. PCR products were electrophoretically separated on either 6% or 8% denaturing polyacrylamide gels. Tumor specimens were scored as having LOH when the decrease in signal intensity in the densitometric tracing was greater than 50%.
Analysis of p53 mutations
PCR-single strand conformation polymorphism (SSCP) analysis using genomic DNA as described previously was performed to detect p53 mutations in the region between exons 5 and 8 (Horio et al., 1993) . Part of the cases enrolled in the present study had previously been evaluated for the presence of p53 mutations. The oligonucleotide primers and PCR conditions used were identical to those detailed in a previous report of ours (Horio et al., 1993) . Repeated SSCP analyses using the products of separate PCR ampli®cations of both normal and tumor cDNAs were conducted to con®rm the somatic nature of the mutations. In addition, in the majority of cases which had demonstrated the presence of altered mobility shifts in the PCR ± SSCP analysis, this presence was further con®rmed by separate PCR and subsequent sequencing analysis as described previously (Horio et al., 1994; Suzuki et al., 1992) .
